Monkeypox: WHO Advises Antiviral Use In Trials Or Expanded Access Programs
With more than 1,200 confirmed cases of monkeypox in 28 non-endemic countries and disease incidence also rising in Africa, the WHO and the US CDC have each updated their guidance on the use of antiviral products. The US has just ordered 500,000 more doses of Bavarian Nordic's smallpox vaccine, Jynneos.
You may also be interested in...
Deal Snapshot: The contract for Tembexa, which builds on an existing deal between Chimerix and Emergent BioSolutions, illustrates lucrative potential opportunities for emergency preparedness.
With limited supplies of vaccines available, manufacturers are being asked to provide the World Health Organization with their smallpox and monkeypox vaccine research plans, existing stocks of vaccine, and current production capacity.
The UK says a “proportionate” approach to tackling monkeypox is needed, and that Imvanex is now available for vaccination. France has issued a decree authorizing the use of Imvanex and the importation of its US equivalent, Jynneos, and Germany has ordered thousands of doses of the vaccine. SIGA’s antiviral tecovirimat can also be used for monkeypox in the EU.